Abstract Search

ey0016.5-8 | Clinical Advances in Treatment | ESPEYB16

5.8. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

EA Imel , FH Glorieux , MP Whyte , CF Munns , LM Ward , O Nilsson , JH Simmons , R Padidela , N Namba , HI Cheong , P Pitukcheewanont , E Sochett , W Hogler , K Muroya , H Tanaka , GS Gottesman , A Biggin , F Perwad , M Mao , CY Chen , A Skrinar , J San Martin , AA Portale

Abstract: Lancet. 2019 May 16.In brief: In a randomised, active-controlled, open-label, phase 3 trial, burosumab (an anti-FGF23 antibody) demonstrated significantly greater clinical improvements in rickets severity, growth, and biochemistries among children with X-linked hypophosphataemia compared with continuation of conventional therapy with oral phosphate and active vitamin D ...

0 shares

ey0015.9-8 | Growth, growth hormone and puberty in chronic diseases: novel insights from clinical practice | ESPEYB15

9.8 Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

J Guzman , T Kerr , LM Ward , J Ma , K Oen , AM Rosenberg , BM Feldman , G Boire , K Houghton , P Dancey , R Scuccimarri , A Bruns , AM Huber , K Watanabe Duffy , NJ Shiff , RA Berard , DM Levy , E Stringer , K Morishita , N Johnson , DA Cabral , M Larché , RE Petty , RM Laxer , E Silverman , P Miettunen , AL Chetaille , E Haddad , L Spiegel , SE Turvey , H Schmeling , B Lang , J Ellsworth , SE Ramsey , J Roth , S Campillo , S Benseler , G Chédeville , R Schneider , SML Tse , R Bolaria , K Gross , D Feldman , B Cameron , R Jurencak , J Dorval , C LeBlanc , C St Cyr , M Gibbon , RSM Yeung , CM Duffy , LB Tucker

To read the full abstract: Pediatr Rheumatol Online J. 2017Aug 22;15(1):68This large prospective study analysed growth in children with JIA during a 3-year period from diagnosis. Interesting findings emerge: the heights and weights of these patients, clearly compromised in historical cohorts, appeared nearly normal. Increased risk of growth impairment was noted in patients with systemic arthr...

0 shares

ey0021.9-16 | Bone Health and Chronic Diseases | ESPEYB21

9.16. Vertebral body reshaping after fractures: an important index of recovery in glucocorticoid-treated children

J Ma , K Siminoski , JL Jaremko , K Koujok , MA Matzinger , N Shenouda , N Wilson , M Cheng , N Alos , S Atkinson , EA Cummings , J Ho , C Rodd , AM Sbrocchi , R Stein , R Barr , E Cairney , DB Dix , CV Fernandez , R Grant , J Halton , S Israels , C Laverdiere , VA Lewis , DA Cabral , A Huber , K Houghton , R Jurencak , B Lang , M Larche , CMA LeBlanc , P Miettunen , J Roth , R Scuccimarri , L Bell , T Blydt-Hansen , G Filler , J Feber , V Phan , K Smit , F Rauch , LM Ward

Brief Summary: This prospective natural history study examined the timing and positive indicators for reshaping of vertebral fractures (VF) in glucocorticoid (GC)-treated patients with chronic diseases. Complete VF reshaping occurred in 82.3% of patients, with similar frequencies in all diagnosis groups (leukemia, rheumatic disorders and nephrotic syndrome) in a median time of 1.3 years. Likelihood of VF reshaping was positively related to higher lumbar spine bone mineral dens...

0 shares

ESPE Yearbook of Paediatric Endocrinology

5.8. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

9.8 Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

9.16. Vertebral body reshaping after fractures: an important index of recovery in glucocorticoid-treated children

BiosciAbstracts